ClinicalTrials.gov
ClinicalTrials.gov Menu

Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01758263
Recruitment Status : Unknown
Verified December 2012 by Forest Laboratories.
Recruitment status was:  Active, not recruiting
First Posted : January 1, 2013
Last Update Posted : January 1, 2013
Sponsor:
Information provided by (Responsible Party):
Forest Laboratories

Brief Summary:
This is a retrospective data analysis of patients with high blood pressure (hypertension) who took metoprolol for a minimum of 6 months who then switched to taking nebivolol for a minimum of 6 month to treat hypertension. These patients will be identified from a large medical claims database. This study tests the hypothesis (alternative, higher or lower) that average patient monthly health care administrative cost changes after switching from metoprolol to nebivolol.

Condition or disease Intervention/treatment
Hypertension Drug: Metoprolol Drug: Nebivolol

Study Type : Observational
Estimated Enrollment : 3000 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment: A Retrospective Database Analysis
Study Start Date : October 2012
Estimated Primary Completion Date : December 2012
Estimated Study Completion Date : July 2013


Group/Cohort Intervention/treatment
Metoprolol to Nebivolol
Patients with high blood pressure (hypertension) who were continuously treated with metoprolol for a minimum of 6 months prior to switching to nebivolol. Patients were then continuously treated with nebivolol for a minimum of 6 months.
Drug: Metoprolol
Metoprolol, oral administration

Drug: Nebivolol
Nebivolol, oral administration




Primary Outcome Measures :
  1. Patient monthly health care cost [ Time Frame: 6 months ]
    The average per patient monthly health care cost for the pre-specified hypertensive target study population during the 6 months before and after switching from metoprolol to nebivolol


Secondary Outcome Measures :
  1. Number of monthly out-patient visits [ Time Frame: 6 months ]
    Estimate the average per patient monthly number of out-patient visits for the pre-specified hypertensive target study population during the 6 months before and after switching from metoprolol to nebivolol.

  2. Monthly Emergency Room visits per patient [ Time Frame: 6 months ]
    Estimate of the average monthly number of Emergency Room (ER) visits per patient for the pre-specified hypertensive target study population during the 6 months before and after switching from metoprolol to nebivolol.

  3. Monthly hospitalizations per patient [ Time Frame: 6 months ]
    Estimate of the average monthly number of hospitalizations per patient for the pre-specified hypertensive target study population during the 6 months before and after switching from metoprolol to nebivolol.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patents treated for hypertension during the period of 2007-2011 in the United States.
Criteria

Inclusion Criteria:

  • Be at least 18 years old at initiation of metoprolol (or first date on metoprolol treatment between 2007 and 2011)
  • Had one or more inpatient or outpatient claims with a primary or non-primary diagnosis of hypertension (ICD-9-CM 401.xx-405.xx)
  • Received nebivolol treatment continuously (defined as supply gap <30 days) for at least 6 months after initiation
  • Received metoprolol treatment continuously for at least 6 months prior to switching to (initiation of) nebivolol (defined as metoprolol was discontinued whereas a prescription for nebivolol was filled)
  • Had at least 12 months of continuous enrollment (as verified using enrollment file): 6 month prior to nebivolol initiation and 6 months following nebivolol initiation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01758263


Locations
United States, New Jersey
Forest Investigative Site 0
Jersey City, New Jersey, United States, 07311
Sponsors and Collaborators
Forest Laboratories
Investigators
Study Director: Stephanie Chen, PhD Forest Laboratories

Responsible Party: Forest Laboratories
ClinicalTrials.gov Identifier: NCT01758263     History of Changes
Other Study ID Numbers: NEB-HE-200
First Posted: January 1, 2013    Key Record Dates
Last Update Posted: January 1, 2013
Last Verified: December 2012

Keywords provided by Forest Laboratories:
Hypertension
Health Care Cost
Monthly health care cost

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Metoprolol
Nebivolol
Anti-Arrhythmia Agents
Antihypertensive Agents
Sympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Adrenergic beta-1 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists